Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.925
+0.065 (3.49%)
At close: Jun 3, 2026, 4:00 PM EDT
1.930
+0.005 (0.26%)
After-hours: Jun 3, 2026, 4:00 PM EDT
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
n/a
Profits / Employee
-$1,725,071
Market Cap
322.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Nautilus Biotechnology | 127 |
| Invivyd | 122 |
| Artiva Biotherapeutics | 104 |
| Neumora Therapeutics | 96 |
| Larimar Therapeutics | 71 |
| InflaRx | 65 |
PALI News
- 7 days ago - Palisade Bio to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 21 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 21 days ago - Palisade Bio files $300M mixed securities shelf - TheFly
- 22 days ago - Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewsWire
- 22 days ago - Palisade Bio Registration statement: Registration filing - Filings
- 22 days ago - Palisade Bio Quarterly report: Q1 2026 - Filings
- 22 days ago - Palisade Bio Earnings release: Q1 2026 - Filings
- 4 weeks ago - Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis - GlobeNewsWire